Modulation of the renin-angiotensin-aldosterone system in heart failure.
作者： J. George , A. D. Struthers , C. C. Lang
DOI: 10.1007/S11883-014-0403-7
关键词: Optimal treatment 、 Medicine 、 Internal medicine 、 Heart failure 、 Clinical trial 、 Angiology 、 Direct Renin 、 Renin–angiotensin system 、 Ejection fraction 、 Cardiology 、 Neprilysin
摘要: The renin-angiotensin-aldosterone system (RAAS) is well-established and continues to be pursued as a therapeutic target in the treatment of heart failure, predominantly due success agents that block RAAS clinical trials systolic failure. optimal failure patients with preserved ejection fraction (HFpEF), however, remains unclear. Early direct renin inhibitors have suggested these may play role HFpEF, but recent trial results not been encouraging. Preliminary angiotensin-receptor/neprilysin look promising. Whether or other drugs will alter current recommendations seen. In this review, we assess understanding modulation
springer.com
core.ac.uk
sci-hub.se 参考文章(70)
Nicholas H.G. Holford, Clinical Pharmacokinetics and Pharmacodynamics of Warfarin. Understanding the Dose-Effect Relationship Clinical Pharmacokinectics. ,vol. 11, pp. 483- 504 ,(1986) , 10.2165/00003088-198611060-00005
Marcin Dominiak, Evidence-based cardiology Ramipryl i telmisartan podobnie skutecznie zapobiegają incydentom wieńcowym – wyniki badania ONTARGET. Commentary to the article: ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59. Kardiologia Polska. ,vol. 66, pp. 705- 706 ,(2008)
Anastassia Goussev, Victor G. Sharov, Hisashi Shimoyama, Mitsuhiro Tanimura, Michael Lesch, Sidney Goldstein, Hani N. Sabbah, Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure American Journal of Physiology-heart and Circulatory Physiology. ,vol. 275, ,(1998) , 10.1152/AJPHEART.1998.275.2.H626
Elena Pavlikova, Pierre J Jordaan, Zhanna Kobalava, Diego Albrecht, Valentin Moiseev, Priyamvada Chandra, Aimen Feng, Oleg Averkov, Abstract 19378: First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure Circulation. ,vol. 122, ,(2010)
R M Fryer, J Segreti, P N Banfor, D L Widomski, B J Backes, C W Lin, S J Ballaron, B F Cox, J M Trevillyan, G A Reinhart, T W von Geldern, Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin‐mediated angioedema British Journal of Pharmacology. ,vol. 153, pp. 947- 955 ,(2008) , 10.1038/SJ.BJP.0707641
Faiez Zannad, Angiotensin-converting enzyme inhibitor and spironolactone combination therapy: New objectives in congestive heart failure treatment American Journal of Cardiology. ,vol. 71, ,(1993) , 10.1016/0002-9149(93)90243-6
Lars H. Lund, Lina Benson, Ulf Dahlström, Magnus Edner, Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. ,vol. 308, pp. 2108- 2117 ,(2012) , 10.1001/JAMA.2012.14785
Anne-Mari Moilanen, Jaana Rysä, Raisa Serpi, Erja Mustonen, Zoltán Szabò, Jani Aro, Juha Näpänkangas, Olli Tenhunen, Meeri Sutinen, Tuula Salo, Heikki Ruskoaho, (Pro)renin Receptor Triggers Distinct Angiotensin II-Independent Extracellular Matrix Remodeling and Deterioration of Cardiac Function PLoS ONE. ,vol. 7, pp. e41404- ,(2012) , 10.1371/JOURNAL.PONE.0041404
B. A. Borlaug, W. J. Paulus, Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment European Heart Journal. ,vol. 32, pp. 670- 679 ,(2011) , 10.1093/EURHEARTJ/EHQ426
M A Konstam, M F Rousseau, M W Kronenberg, J E Udelson, J Melin, D Stewart, N Dolan, T R Edens, S Ahn, D Kinan, Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. ,vol. 86, pp. 431- 438 ,(1992) , 10.1161/01.CIR.86.2.431